Products - Oesophageal cancer | Topic

Showing 14 products

Date | Sort by Title

Guidance programme: Technology appraisal guidanceRemove ‘Guidance programme: Technology appraisal guidance’ filter

Ramucirumab for treating advanced gastric cancer or gastro–oesophageal junction adenocarcinoma previously treated with chemotherapy (TA378)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published date:
27 January 2016
Nivolumab for previously treated unresectable advanced oesophageal cancer [ID1249]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
13 January 2021
Nivolumab for previously treated gastric or gastro-oesophageal junction cancer [ID1118]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Pertuzumab for untreated metastatic HER2-positive gastric or gastro-oesophageal junction cancer [ID1096]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Pembrolizumab for previously treated metastatic gastric or gastro-oesophageal junction cancer ID1168
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Avelumab for treating gastric or gastro-oesophageal junction cancer after 2 therapies ID1289
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Pembrolizumab for gastric or gastroesophageal junction adenocarcinoma ID1305
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Pembrolizumab for previously treated oesophageal or gastro-oesophageal junction cancer ID1357
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Trifluridine–tipiracil for treating metastatic gastric or gastro-oesophageal junction cancer after 2 or more therapies [ID1507]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Nivolumab with cisplatin and fluorouracil for untreated advanced oesophageal squamous cell carcinoma [ID2712]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Nivolumab with ipilimumab for untreated unresectable metastatic oesophageal squamous cell carcinoma [ID1629]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Pembrolizumab with chemotherapy and surgery for treating resectable gastric or gastro-oesophageal junction cancer [ID2696]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Pembrolizumab with fluoropyrimidine and cisplatin for treating recurrent advanced oesophageal cancer [ID3741]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Pembrolizumab with trastuzumab and chemotherapy for untreated HER2-positive advanced gastric or gastro-oesophageal junction cancer [ID3742]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC

Oesophageal cancer Products

Filter

Product type

Guidance programme
1 selected

Status

New and updated

Showing 14 products

Ramucirumab for treating advanced gastric cancer or gastro–oesophageal junction adenocarcinoma previously treated with chemotherapy (TA378)

Nivolumab for previously treated unresectable advanced oesophageal cancer [ID1249]

Nivolumab for previously treated gastric or gastro-oesophageal junction cancer [ID1118]

Pertuzumab for untreated metastatic HER2-positive gastric or gastro-oesophageal junction cancer [ID1096]

Pembrolizumab for previously treated metastatic gastric or gastro-oesophageal junction cancer ID1168

Avelumab for treating gastric or gastro-oesophageal junction cancer after 2 therapies ID1289

Pembrolizumab for gastric or gastroesophageal junction adenocarcinoma ID1305

Pembrolizumab for previously treated oesophageal or gastro-oesophageal junction cancer ID1357

Trifluridine–tipiracil for treating metastatic gastric or gastro-oesophageal junction cancer after 2 or more therapies [ID1507]

Nivolumab with cisplatin and fluorouracil for untreated advanced oesophageal squamous cell carcinoma [ID2712]

Nivolumab with ipilimumab for untreated unresectable metastatic oesophageal squamous cell carcinoma [ID1629]

Pembrolizumab with chemotherapy and surgery for treating resectable gastric or gastro-oesophageal junction cancer [ID2696]

Pembrolizumab with fluoropyrimidine and cisplatin for treating recurrent advanced oesophageal cancer [ID3741]

Pembrolizumab with trastuzumab and chemotherapy for untreated HER2-positive advanced gastric or gastro-oesophageal junction cancer [ID3742]

Oesophageal cancer Products

Filter

Product type

Guidance programme1 selected

Status

New and updated

Showing 14 products

Guidance programme
1 selected